首页> Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy> Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.

Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.

导出原文传递

翻译打印收藏纠错

第一作者： Suzy E,Meijer

第一单位： Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: suzymeijer@gmail.com.

作者： Suzy E,Meijer ^[1] ; Ora,Halutz ^[2] ; Amos,Adler ^[2] ; Katya,Levytskyi ^[2] ; Luba,Tau ^[2] ; Michal,Dekel ^[2] ; Ronit,Cohen-Poradosu ^[3] ; Evgene,Katchman ^[2] ; David,Shasha ^[2] ; Jacob,Ablin ^[2] ; Guy,Choshen ^[4] ; Giris,Jacob ^[2] ; Asaf,Wasserman ^[2] ; Merav,Ingbir ^[2] ; Yael C,Cohen ^[2] ; Chava,Perry ^[2] ; Ron,Ram ^[2] ; Yair,Herishanu ^[2] ; Yael,Bar On ^[5] ; Elma,van Thijn ^[6] ; Natalie,Rutsinsky ^[7] ; Sheri,Harari ^[7] ; Adi,Stern ^[7] ; Ronen,Ben-Ami ^[2] ; Yael,Paran ^[2]

作者单位： Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: suzymeijer@gmail.com. ^[1] Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. ^[2] Kaplan Medical Center, Rehovot, Israel. ^[3] Meir Medical Center, Kfar Saba, Israel. ^[4] Shaare Zedek Medical Center, Jerusalem, Israel. ^[5] grade Up, Amsterdam, The Netherlands. ^[6] The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. ^[7]

关键词 Dual anti-viral therapy Hemato-oncological patients Immunocompromised patients Persistent COVID-19

医学主题词人类(Humans);男(雄)性(Male);老年人(Aged);女(雌)性(Female);预后(Prognosis);时间因素(Time Factors);抗病毒药(Antiviral Agents)

DOI 10.1016/j.jiac.2023.10.022

PMID 37944697

发布时间 2024-02-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交